Could your own antibodies make a respiratory infection worse?
NCT ID NCT05536219
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study investigates whether certain autoantibodies that block the body's natural antiviral defenses lead to higher viral levels and slower recovery in severe respiratory infections like flu, RSV, and COVID-19. Researchers will measure viral load changes over a week in 360 ICU patients (adults and children) to understand why some people develop severe illness. The goal is to uncover immune system weaknesses that could guide future treatments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 360 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Nov 2022
- Expected to finish
-
Aug 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Adult patients and pediatric patients admitted to intensive care unit with acute respiratory failure induced by RSV, influenza or SARS-Cov-2 viral infection (for adults only) or in respiratory distress placed on oxygen with suggestive sign(s) of viral infection for minors only.
- Ages
-
Children (under 18), adults (18 to 64) and older adults (65 and over)
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: For adult patients : * Patients with acute respiratory failure requiring the administration of oxygen\* to maintain peripheral oxygen saturation at at least 90% \* in patients with chronic respiratory failure, an oxygen flow higher than the usual flow or a duration of non-invasive ventilation longer than the usual duration will be required. * Patients with influenza, RSV or SARS-CoV-2 infection diagnosed by Reverse Transcription Polymerase Chain Reaction (RT-PCR) or antigen test in the last 7 days * Patients hospitalized in participating intensive care units For pediatric patient : * In respiratory distress placed on oxygen with signs suggestive of viral infection: 1. moderate or absent fever or nasopharyngeal congestion or cough 2. signs of acute respiratory distress (polypnea \> 2DS of the normal value, intercostal drawing, thoraco-abdominal sway) with more or less marked hypoxia (SpO2 \< 92% under ambient air), 3. and/or significant apnea (associated with bradycardia or desaturation), 4. and/or dietary difficulties (reduction of rations to less than 50% of the usual ration). * Hospitalized in the pediatric emergency and intensive care unit of Hôpital Femme Mère Enfant (HFME) Exclusion Criteria: * Opposition of the patient or his close family/friend to inclusion in the study * Patient under legal protection measure * Patient who was included in this study during a previous stay * Immunodepression defined by: bone marrow allograft less than 24 months old, chemotherapy for less than 6 months, HIV infection with CD4\<200/mm3 or \<15%, corticosteroid therapy for more than 2 weeks with a daily dose greater than 10 mg of prednisolone equivalent, immunosuppressive treatment administered in the previous 3 months (6 months for rituximab), aplasia, asplenia or splenectomy. * Patient under 30 kg (for adults) and less than 3 kg (for children)
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Severe respiratory infections are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
3 sites. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Hopital Lyon Sud
RECRUITINGPierre-Bénite, Rhone, 69110, France
-
Hôpital Croix Rousse
RECRUITINGLyon, Rhône, 69004, France
-
Hôpital Femme Mère et enfant
RECRUITINGBron, Rhone, 69500, France